Zhong Guo Jing Ji Wang·2025-07-19 07:37Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has passed the IPO review by the Shanghai Stock Exchange, marking it as the 34th company to receive approval this year [1] Company Overview - Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with a commitment to developing transformative solutions [1] - The company has launched 11 products to date and has 6 products under development, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [1] Shareholding Structure - The company has no controlling shareholder, with the actual controller being Song Liang, who holds 16.1530% of the shares directly and controls an additional 13.4140% through partnerships, totaling 29.5670% of voting rights [2] - Other shareholders are primarily financial investors who have committed not to seek control of the company, recognizing Song Liang's position as the actual controller [2] Management and Governance - Song Liang is the core founder and has served as the chairman and CEO, significantly influencing the selection of board members and daily management decisions [3] - The company plans to publicly issue up to 90 million shares on the Sci-Tech Innovation Board, with a minimum of 10% of the total share capital post-issue [3] Fundraising Plans - Beixin Life aims to raise approximately 95.22113 million yuan, which will be allocated to the construction of a medical device industrialization base, R&D projects, and to supplement working capital [3] Market Position and Competitive Landscape - The IPO review committee raised questions regarding the market space, competitive landscape, and sustainability of the company's core products, specifically FFR and IVUS [4]